Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

The gene therapy for an undisclosed central nervous system disease is based on JCR's delivery technology and Modalis' epigenome editing platform.

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

The gene therapy focuses on a critical heart protein called cardiac bridging integrator 1 (cBIN1). Reduced levels of cBIN1 impair the heart muscle’s ability to contract. Previous studies have ...

In the coming year, regulatory authorities in the US are expected to approve a pig gene-edited to make it resistant to a common and devastating disease. That approval could open the door to a much ...

In an effort to increase protein levels in heart failure, the researchers turned to a harmless virus commonly used in gene therapy to deliver an extra copy of the cBIN1 to heart cells. The virus ...

12 Dec Heart failure is reversed with new gene therapy in animal study: ‘Unprecedented recovery’ Fox News 14:48 Wed, 11 Dec TikkunLev Therapeutics Announces the Publication of a Seminal Study in ...

“It’s going back to what the normal heart should look like.” The gene therapy focuses on a critical heart protein called cardiac bridging integrator 1 (cBIN1). Reduced levels of cBIN1 impair the heart ...

BHUBANESWAR: In a significant medical breakthrough, India’s first human gene therapy with a lentiviral vector for severe haemophilia-A has been found to be successful with zero bleeding rate in ...

BUFFALO, N.Y. (WIVB) — The state’s first cell and gene therapy hub is right here in Buffalo. Gov. Kathy Hochul celebrated the opening of the $98 million Roswell Park GMP Engineering and Cell ...